Non‐Dopaminergic Approaches to the Treatment of Parkinson's Disease

Fox, Susan H.; Brotchie, Jonathan M.

doi:10.1002/9781444397970.ch38

Cited by 1 publication

(1 citation statement)

References 281 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The opioid neurotransmission system is prominent in the basal ganglia. Endogenous opioid peptides and their precursors are highly expressed within the basal ganglia where they are modulators of GABA, DA, and glutamate neurotransmission (Fox et al, 2006; Fox & Brotchie, 2011). Several lines of evidence suggest that κ-mediated opioid signaling is overactive in LID.…”

Section: Discussionmentioning

confidence: 99%

Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion

Flores,

Bartlett,

Samtani

et al. 2023

Preprint

View full text Add to dashboard Cite

Levels of the opioid peptide dynorphin, an endogenous ligand selective for kappa-opioid receptors (KORs), its mRNA and pro-peptide precursors are differentially dysregulated in Parkinson disease (PD) and following the development of L-DOPA-induced dyskinesia (LID). It remains unclear, whether these alterations contribute to the pathophysiological mechanisms underlying PD motor impairment and the subsequent development of LID, or whether they are part of compensatory mechanisms. We sought to investigate nor-BNI, a KOR antagonist, 1) in the dopamine (DA)-depleted PD state, 2) during the development phase of LID, and 3) with measuring tonic levels of striatal DA. Nor-BNI (3 mg/kg; s.c.) did not lead to functional restoration in the DA-depleted state, but a change in the dose-dependent development of abnormal voluntary movements (AIMs) in response to escalating doses of L-DOPA in a rat PD model with a moderate striatal 6-hydroxydopamine (6-OHDA)lesion. We tested five escalating doses of L-DOPA (6, 12, 24, 48, 72 mg/kg; i.p.), and nor-BNI increased the development of AIMs at the lower doses (12 and 24 mg/kg L-DOPA). However, after dosing with 72 mg/kg L-DOPA, AIMs were not significantly different between control and nor-BNI groups. In summary, while blocking KORs significantly increased the rate of development of LID induced by chronic, escalating doses of L-DOPA in a moderate-lesioned rat PD model, it did not contribute further once the overall severity of LID was established. While we saw an increase of tonic DA levels in the moderately lesioned dorsolateral striatum, there was no tonic DA change following administration of nor-BNI.

show abstract

Section: Discussionmentioning

confidence: 99%